Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, July 12, 2017
[ Wed, Jul 12th 2017
] - WOPRAI
[ Wed, Jul 12th 2017
] - WOPRAI
[ Wed, Jul 12th 2017
] - WOPRAI
[ Wed, Jul 12th 2017
] - WOPRAI
Tue, July 11, 2017
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
[ Tue, Jul 11th 2017
] - WOPRAI
Mon, July 10, 2017
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
David Lewis Maintained (ABT) at Hold with Increased Target to $49 on, Jul 10th, 2017
David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Hold with Increased Target from $45 to $49 on, Jul 10th, 2017.
David has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Isaac Ro of "Goldman Sachs" Initiated at Hold and Held Target at $45 on, Tuesday, May 16th, 2017
- Joanne Wuensch of "BMO Capital" Downgraded from Buy to Hold on, Tuesday, March 14th, 2017
This is the rating of the analyst that currently disagrees with David
- Christopher Pasquale of "Guggenheim" Initiated at Strong Buy and Held Target at $58 on, Thursday, June 29th, 2017
Similar Stocks and Investing Articles
[ Thu, Jun 29th 2017
] - WOPRAI
[ Thu, Jul 07th 2016
] - WOPRAI
[ Mon, Jul 21st 2014
] - WOPRAI
[ Tue, Jan 14th 2014
] - WOPRAI
[ Wed, May 23rd 2012
] - WOPRAI
[ Fri, Apr 27th 2012
] - WOPRAI
[ Fri, Apr 27th 2012
] - WOPRAI
[ Wed, Apr 11th 2012
] - WOPRAI
[ Fri, Mar 16th 2012
] - WOPRAI